Aizawa T, Itoh T, Tsujino S, Namiki K, Miki M
Department of Urology, Tokyo Medical College, Shinjuku.
Kaku Igaku. 1992 Nov;29(11):1277-83.
Seventy-seven patients with prostatic cancer were treated at our department in the last 5 years. Of these patients 30 cases were followed by bone scintigraphy and serum PAP. In 27 follow-up scintigraphy procedures changes of bone scintigraphy corresponded to changes in serum PAP levels Changes of PAP levels did not always correspond to changes of scintigraphy, but almost all cases in which the level of PAP increased in a short period showed progression of bone metastasis. A 3-month interval between bone scintigraphy procedure in stage D2 prostatic cancer patients is generally recommended. However, we think that in prostatic cancer patients follow-up bone scintigraphy at regular short intervals is unnecessary if there is no change in serum PAP levels, symptoms or physical condition. Bone scintigraphy should be performed when the tumor marker changes rapidly or when any physical symptom appears.
在过去5年里，我们科室共治疗了77例前列腺癌患者。其中30例患者接受了骨闪烁扫描和血清前列腺酸性磷酸酶（PAP）检测。在27次随访骨闪烁扫描过程中，骨闪烁扫描的变化与血清PAP水平的变化相对应。PAP水平的变化并不总是与闪烁扫描的变化一致，但几乎所有短期内PAP水平升高的病例都显示有骨转移进展。一般建议D2期前列腺癌患者的骨闪烁扫描检查间隔为3个月。然而，我们认为，如果血清PAP水平、症状或身体状况没有变化，前列腺癌患者没有必要定期进行短期的随访骨闪烁扫描。当肿瘤标志物迅速变化或出现任何身体症状时，应进行骨闪烁扫描。
